PERSEUS1
PERSEUS1 investigates a new treatment for people with advanced prostate cancer.
Disease site: Prostate cancer
Status: In follow-up
What is the study about?
PERSEUS1 investigates a new treatment for people with advanced prostate cancer.
Pembrolizumab is a type of treatment called an immunotherapy. It works by reactivating the body’s immune system to attack the cancer cells. It may work best for people whose cancer cells have an abnormality (mutation) which either helps to deactivate the immune system or reduces cells’ ability to repair DNA.
The results of this study will indicate whether pembrolizumab is an effective treatment for people who have advanced prostate cancer with a mutation.
Who is included in the study?
PERSEUS1 includes people with advanced prostate cancer whose treatment is no longer working. Everyone in the trial will have cancer with a mutation which means pembrolizumab may work for them. This mutation may have been found in a screening study like MAESTRO. Up to 100 people from NHS hospitals in the UK will join the study.
What are the study treatments?
Everyone who joins the trial will receive pembrolizumab treatment for up to two years. Participants have regular check ups during and after their treatment and we collect information about how they are getting on until the study is completed.
Further information for participants
A detailed summary is available on Cancer Research UK’s website
Further information for healthcare professionals
Contact details and regulatory information
Chief Investigator: Professor Johann de Bono, The Institute of Cancer Research
ICR-CTSU Scientific Lead: Professor Christina Yap
Trial management contact: [email protected]
Sponsor: The Institute of Cancer Research
Funding: Merck Sharp and Dohme (MSD)
Trial identifiers
EUDRACT number: 2017-000931-15
REC reference: 18/LO/0825
CPMS ID: 37624
ClinicalTrial.gov: NCT03506997
Publications and Presentations
P. Rescigno, M. Dolores Fenor de la Maza, S. Burnett, G. Villacampa, M. Stiles, F. Cafferty, N. Beije, S. Carreira, I. Figueiredo, P. Flohr, B. Gurel, C. Bertan, D. Westaby, K. Chandran, M. Crespo, C. Perna, N. Tunariu, A. Sharp, C. Yap, and J. De Bono (2024). Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).
ASCO Genitourinary Cancers Symposium 2024, San Francisco, USA. Poster presentation, January 2024.
S. Burnett, N. Porta, A. Sarvadikar, A. Gillman, P. Flohr, I. Figueiredo, A. Sharp, P. Rescigno, J. De Bono and E. Hall (2019). Designing and implementing a phase II targeted treatment platform study: a modular approach in metastatic Castration Resistant Prostate Cancer (mCRPC).
International Clinical Trials Methodology Conference 2019, Brighton, UK. Oral presentation, October 2019.
P. Rescigno, S. Burnett, N. Porta, A. Sarvadikar, P. Flohr, I. Figueiredo, D. Bianchini, S. Carreira, R. Riisnaes, S. Miranda, M. Crespo, B. Gurel, M. Lambros, C. Bertan, M. Clarke, G. Seed, A. Ferreira, A. Da Silva Pereira, E. Hall and J. De Bono (2019). MAESTRO/PERSEUS: A phase II molecular stratification/treatment platform in Metastatic Castration Resistant Prostate Cancer (mCRPC) – PERSEUS1 (pembrolizumab; NCT03506997).
National Cancer Research Institute (NCRI) Conference 2019, Glasgow, UK. Poster presentation, November 2019.
Remembering former ICR Chief Executive Professor Peter Garland
